TRAF3IP2-AS1 functions as a tumor suppressor in NONO-TFE3 tRCC progression and may serve as a novel target for NONO-TFE3 tRCC therapy. This evidence concerns the gene TRAF3IP2 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.